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Introduction
An audacious theory proposes the existence of a novelform of life—the nanobacteria (NB)—that is quitedifferent from the ones already known, but is
capable of infecting and damaging other beings, thus
qualifying them as new agents of emerging infectious
diseases.
The theory is no less revolutionary than the famous germ
theory of disease, which was put on solid ground by the
efforts of Pasteur and Koch, or the one on contagium vivum
fluidum, which heralded the birth of virology.
Other extraordinary findings have appeared in the recent
scientific literature; some have opened new perspectives and
have led to immense areas of new knowledge, while others,
like cold fusion or the memory of water, have passed like
meteors, and are remembered as minor happenings of little
hindrance to the steady advancement of science.
What about NB? Are they going to be marked as milestones,
or, as we fear, are they going to linger about for decades as
UFOs have?
‘‘Nanobacteria’’ is a neologism, introduced and patented by
Dr. Olavi Kajander as the name for very small bacteria-like
organisms. In 1998, a seminal paper in PNAS [1] by Kajander
and Neva Ciftcioglu boldly announced the discovery of an
unprecedented form of life having something in common
with bacteria, but so much different from the ones already
known that it deserved a new name. On account of their
mineralizing properties, nanobacteria have also been called
calcifying nano-particles [2].
Kajander and colleagues had worked for years on their
invention, but their reports were turned down by the
microbiological establishment because they went against
accepted paradigms. The technical details of the methods
originally used to define the key features of the purported
novel organism have thus been presented orally, or published
in obscure journals or proceedings, and their abstracts have
often been taken uncritically at their face value. Galileo
Galilei was vindicated by history, Kajander and Ciftcioglu so
far only by the Web: in a Google search of July, 2003 they got
3,160 hits for ‘‘nanobacteria’’; with the same keyword, we now
(as of January 8, 2007) get 90,500 hits with Google, and
198,000 with Yahoo.
Another obstacle to the equitable assessment of the
evidence is the fact that its main contributors have—
legitimately—started a diagnostics and pharmaceutical
business enterprise, and their papers do not always state their
business connections.
Distribution and Disease Association
NB have been reported to be present in animal [3,4] and
human blood [5], in bile [6], in tissue culture cell lines [7], in
wastewater [8], in Australian sandstones, in the stratosphere
[9], and in meteorites [10]. Most of the reports are based on
the visualization of nanobacteria by scanning electron
microscopy, but some are supported by their propagation in
cell-free media, according to the inventors.
Whereas some of the findings have given rise to highly
speculative lines of thought, with hypotheses about their
extraterrestrial origin or their primordial role in the
development of life on Earth, we are more interested in the
nature of NB and in their purported association with
pathological conditions.
In line with the experimental demonstration that NB are
efficient nuclei of mineralization that start the formation of
apatite from soluble calcium and phosphorus compounds at
physiologic concentrations and conditions, many authors
have followed Kajander’s lead [1,11,12] and reported NB in
association with a variety of pathological calcifications,
notably nephrolithiasis [13,14], cholecystolithiasis [15],
vascular plaques [16,17], valvular calcification [18],
psammoma bodies in ovarian cancers [19], mammary cancer
[20] and breast implant contracture [21], osteoarthritis [22],
chronic prostatitis and prostate stones [23], and periodontal
disease [24]. NB have also been implicated in intervertebral
disk degeneration [25], polycystic kidney disease [26,27],
reduced bone density in HIV [28], and peripheral neuropathy
[29].
It is a fact that the process of pathological calcifications is
largely unknown, and the idea that it might be due to some
novel form of life is appealing but provocative. Most of the
cited reports assume that NB do exist and that they are living
organisms with the peculiar properties described by Kajander
and collaborators; few of them, notably the papers by Cisar et
al. [30] and Drancourt et al. [31], challenge the assumption;
only the paper by Miller et al. [17] brings new and
independent experimental data to support it.
Ontology of NB
According to their discoverers [7], NB are very minute
bodies ranging in size from 20 to 500 nm, the smaller ones
filterable through membranes with 100-nm pores, and are
observable by scanning electron microscopy or transmission
Editor: Marianne Manchester, The Scripps Research Institute, United States of
America
Citation: Urbano P, Urbano F (2007) Nanobacteria: Facts or fancies? PLoS Pathog
3(5): e55. doi:10.1371/journal.ppat.0030055
Copyright:  2007 Urbano and Urbano. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Abbreviation: NB, nanobacteria
Pasquale Urbano is full Professor of Microbiology at the Medical School of the
University of Florence, Florence, Italy, and Director of its Department of Public
Health. Francesco Urbano serves as Major (OF3) at the Logistic Headquarters,
Medical Branch, Italian Army Medical Corps, Rome, Italy, and is a lecturer on
infectious diseases at the University of Florence, Florence, Italy.
* To whom correspondence should be addressed. E-mail: pasquale.urbano@unifi.it
PLoS Pathogens | www.plospathogens.org May 2007 | Volume 3 | Issue 5 | e550567
electron microscopy, where they appear as spheres or rods.
Many others have observed such bodies in diverse substrates
and have called them nanoforms, nannobacteria,
nanoparticles, nano-organisms, nanobes, living nanovesicles,
microfossils, etc. The hallmark of NB is their more or less
thick coat of apatite, which is formed from soluble calcium
and phosphorus compounds in their environment or
medium.
Ciftcioglu and Kajander came across NB as cytopathic
contaminants of cell cultures; their early findings are
recapitulated in a 1998 paper [7], which emphasizes the fact
that traditional microbiological methods fail to reveal NB,
and that specific methods had to be invented for their
detection and culture; they had already patented such
methods in 1992. In short, they developed a new culture, DNA
staining, and immunoassay methods, by which they convinced
themselves, and tried to convince others, that they had
discovered a new living organism, or at least ‘‘the smallest
culturable autonomously replicating agent on Earth’’ [32].
This very claim was theoretically audacious [33,34], and it
instigated the reaction of traditional biologists, who reached
a consensus about the admissible lower size limit of a
microorganism [35]; the idea that the machinery necessary for
sustaining life as we presently know it could fit in a 20-nm
sphere was flatly rejected.
Another key trait of Kajander’s NB is their apparent
culturability in cell-free media, typically the ones normally
adopted for cell cultures, like Dulbecco minimal essential
medium or RPMI-1640, with or without fetal calf serum or
other supplement. This kind of propagation has succeeded in
the hands of many independent researchers, notably of Cisar
et al. [29], who, however, give an alternative interpretation of
NB-induced mineralization, and find no evidence for the
living nature of NB. Experienced microbiologists who had
failed to substantiate the positive findings [31] received a
piquant rebuttal [36].
The filterability of NB is another stronghold of the NB
addicts; of course, there is no question about nano-sized
particles being able to go through 0.1-l pores. The point is
their being able to replicate in the sense which is normally
given to the word. The prion scrapie protein is filterable and
it will propagate in the presence of the normal prion protein,
but not by binary scission, as bacteria do. At any rate, the
filterability of microorganisms is a long-lasting and unsettled
argument [37].
NB are said to be immunogenic, and kits for the detection
of their antigen or antibodies have been developed by
NanoBac Oy, Kuopio, Finland; the specificity of the
proprietary immunological reagents is controversial, as is the
evidence based on their use.
New experimental data by Miller et al. [17], working with
NB propagated from vascular calcifications, have been
construed to demonstrate the organismic nature of NB on the
basis that they contain DNA, synthesize proteins and at least
one NB antigen, and incorporate uridine, albeit at very low
levels, barely above the negative controls.
Almost nothing is known about the metabolism of NB; they
are said to double in one to five days, mostly on the basis of
rising optical density or of increasing mineral mass. Nucleic
acid presence and metabolism is controversial, as standard
methods are said to be inadequate to their study. The
sequence of a putative 16S rDNA PCR amplicon was hastily
proposed as the basis for establishing a new genus and
species, Nanobacterium sanguineum, which was placed in the a-2
subgroup of Proteobacteria, which also includes Brucella and
Bartonella species. The European Molecular Biology
Laboratory (EMBL) X98418 and X98419 files in the EMBL
database cannot be opened at present, while a search in the
Deutsche Sammlung Von Mikroorganismen Und Zellkulturen
(DSMZ) catalogue for the material deposited with number
5819-5821 yields no answer.
After Cisar et al. [30] suggested that the published sequence
came from a contaminant, it became clear that there is no
sound basis for the existence of Nanobacterium sanguineum, and
the name has no standing in the nomenclature. Kajander
himself recently admitted that the bacterial status of NB is
still lacking satisfactory evidence, and he concedes that the
term ‘‘calcifying nanoparticle’’ best describes the agent [38];
unfortunately, he also still uses the untenable word
‘‘nanobacteria’’, which landed him in a microbial minefield,
as an editorial had rightly foreseen [39]. In his retreat he
establishes a second line of defence, insisting that calcifying
nanoparticles are infectious agents, not Eubacteria or Archea,
but entities of their own, perhaps of primordial origin. In this
he follows the wild hypotheses of Sommers, a prolific writer
whose papers deserve a review of their own [28,29].
We try to keep an open mind and we accept the idea that
new evidence may extend the limits of our knowledge, and
even overturn long-accepted paradigms; however, we believe
that in so doing it is not acceptable to misuse words and
concepts that have their foundation in the current paradigm.
To be clear, it is a fact that in Kajander’s PNAS paper [1],
Figure 1E depicts an unknown bacterium, and that other,
seemingly different, bacteria are depicted in various papers
by the Nanobac group; nothing proves that they are one and
the same entity as the much smaller pleomorphic
nanoparticles. It is also a fact that nothing has been done to
identify or to characterize it, or them; nowhere have we found
that NB have been ‘‘isolated’’, and we know that in the mid-
1800s, the revolutionary germ theory of disease would not
have been accepted without the cumbersome methods set up
by Pasteur for obtaining pure cultures, and it would not have
gained impetus without the isolating cultures on the solid
media of Koch.
Also untenable is the idea that any trait observed on NB,
whatever their source, may be attributable to a single entity,
and that this piecemeal evidence, every piece of which is
debatable, can ever lead to sound knowledge. For instance,
how does one reconcile the report that the cell wall of NB is
twice as thick as that of Staphylococcus epidermidis [40], with the
often-cited Gram negativity of NB? And what is the basis for
their asserted motility? The catalase negativity—in fact, any
enzyme negativity whatsoever—adds nothing to what we
know about NB.
Risk and Disease Association
The inventors of NB strongly promote the idea that they
are infectious pathogens and that they represent a global
health risk. However, there is a problem with the semantics,
the concept of infection being stretched beyond its
traditional meaning of parasitic symbiotic relationship. Still,
pragmatism forces us to consider that calcifying particles
could in fact be involved in pathological processes, serving as
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crystallization nuclei. In view of the quasi-ubiquity of NB,
proof of their etiologic or pathogenic role is going to be a
formidable task, to be repeated for each and every disease;
the associations already reported are at best to be considered
working hypotheses, to be confirmed by independent
research with non-proprietary methods and reagents.
Shortcuts are risky; in the era of evidence-based medicine
the time-honoured ex iuvantibus criterion must be exercised
with rigid and formally explicit requisites. The two papers
claiming therapeutic success with a complex anti-NB regimen
that includes comET, a patent ‘‘nutraceutical’’, are not
randomized, controlled, or properly blinded. In particular,
the paper by Maniscalco and Taylor [41] states that 57% of the
treated patients had decreased coronary artery calcification
scores; these patients were labelled ‘‘responders’’, and among
‘‘responders’’, the scores where significantly lower! Nothing is
said about the rest of the study group, and one is left with the
certainty that they had (by definition) stable or increased
scores, perhaps significantly so; such a grossly misleading
presentation of the data verges on quackery.
The paper by Shoskes et al. [23] is a small open label pilot
study; the authors refer to ‘‘the complete resolution of
concomitant CPPS [chronic prostatitis/pelvic pain syndrome]
symptoms’’ anecdotally reported by Maniscalco, before the
publication of the cited paper, but the results are presented
more prudently, and the relationship with Nanobac Life
Science is correctly declared.
The reported wide distribution of NB, their filterability,
and their asserted pathogenicity are strong selling points for
the NB business. The pharmaceutical industry is urged to
look for NB, and to invest in their elimination; vaccines,
blood, and blood derivates should be guaranteed NB-free.
Space flights should take into account that NB grow faster at
microgravity [42], and the US National Aeronautics and
Space Administration already worries about it.
The reported consistent prevalence of NB in the blood of
healthy people is presented as a risk factor for a number of
pathologies. The lay press comes out with best sellers like The
Calcium Bomb, and the Web acts as a bandwagon.
In short, we are experiencing an aggressive risk-mongering
and disease-mongering campaign, and journal referees have
been, are, and will be hard pressed with papers that mix NB
facts with NB fancies; the papers they reject are going to swell
the grey literature, and blogs will be filled with pieces
condemning the obscurantism of the non-believers. &
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